With Ziihera Wins Rolling in, Zymeworks Rolls Out Plan to Become ‘Royalty-Driven Organization’

Zymeworks is shifting to a royalty-driven model after early success with its licensed cancer drug Ziihera. The company plans to rely on cash flows from partners like Johnson & Johnson, GSK, and Bristol Myers Squibb to fund internal R&D and potential acquisitions. By licensing out later-stage assets and focusing on early development, Zymeworks aims to avoid costly pivotal trials and grow its royalty portfolio.